Pharmaceutical Research & Development

Our Drug Pipeline


Our drug research and development pipeline

Our product pipeline reflects our commitment to developing innovative products that help diagnose or treat gastrointestinal disorders. Salix focuses on innovative gastrointestinal products and investigating currently marketed products for new indications. This page features information on the compounds currently in our pipeline. Information on this page is current as of 12/15/2013.


Program Indication Clinical Phases
PHASE 2  PHASE 3
NDA
Under Review
Methylnaltrexone Bromide
MDP (Multi-Dose Pen)
Opioid induced constipation (OIC) in advanced illness  
Methylnaltrexone Bromide SC*
(Subcutaneous Injection)
OIC in chronic non-cancer pain
Methylnaltrexone Bromide
(Oral Formulation)
OIC in chronic non-cancer pain  
Budesonide Foam Ulcerative proctitis or proctosigmoiditis  
Rifaximin
for the treatment of IBS-D
(TARGET 3 - retreatment of
IBS-D)
Irritable bowel syndrome with diarrhea  
Rifaximin EIR
(Extended Intestinal Release)
Crohn's disease
   
Rifaximin SSD
(Soluble Solid Dispersion)
Prevention of complications in compensated liver cirrhosis  
Lumacan Assist in endoscopic detection of precancerous and cancerous lesions in the colon In development
*Most recent regulatory action summarized in the press release dated October 2013.
Most recent regulatory action summarized in the press release dated February 2012.

SWB 13/22-1


Check out our latest Press Releases and News